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ABSTRACT
The Nonsense-mediated mRNA decay (NMD) path-
way selectively degrades mRNAs harboring prema-
ture termination codons (PTCs) but also regulates
the abundance of a large number of cellular RNAs.
The central role of NMD in the control of gene expres-
sion requires the existence of buffering mechanisms
that tightly regulate the magnitude of this pathway.
Here, we will focus on the mechanism of NMD with
an emphasis on the role of RNA helicases in the tran-
sition from NMD complexes that recognize a PTC to
those that promote mRNA decay. We will also review
recent strategies aimed at uncovering novel trans-
acting factors and their functional role in the NMD
pathway. Finally, we will describe recent progress in
the study of the physiological role of the NMD re-
sponse.
INTRODUCTION
Cells have evolved different surveillance mechanisms to tar-
get messenger RNAs (mRNAs) with mutations that would
otherwise lead to errors in the synthesis of proteins, and
also to eliminate other incorrectly processed cellular RNAs.
These mechanisms operate both in the cell nucleus and
cytoplasm (1). One of the best-studied RNA surveillance
pathways is the Nonsense-mediated decay (NMD) path-
way, which targets mRNAs harboring premature termina-
tion codons (PTC) for degradation. This mechanism oper-
ates in the cytoplasm and is intimately linked to translation
termination (2,3).
Initially, NMD was described as a post-transcriptional
mRNA quality control mechanism responsible for the re-
moval of PTC-containing mRNAs, which if left intact,
would lead to production of truncated proteins with pre-
dicted deleterious effects for the organism. From a medi-
cal perspective, this suggests that the NMD pathway has a
role in themodulation of the phenotypic outcome of genetic
disorders that are caused by the presence of a PTC (4,5).
However, it has become evident in recent years that this
pathway is not solely dedicated to the destruction of PTC-
containing transcripts, but that it also has an important role
in controlling the expression of naturally occurring tran-
scripts (6–8) (Figure 1). This general role of the NMDpath-
way on gene expression requires the existence of buffering
mechanisms to tightly regulate the magnitude of the NMD
response upon environmental and/or genetic insults. Ac-
cordingly, a negative feedback regulatory network that con-
trols the levels of core NMD factors operates in mammals
(9,10), in nematodes and zebrafish (11), and also in plants
(12). Interestingly, the magnitude of the NMD response has
also been shown to be variable among individuals (13). The
NMD pathway is not exclusively dedicated to mRNAs, as
shown by the substantial number of long non-codingRNAs
(lncRNAs) that are substrates of NMD in Arabidopsis, S.
cerevisiae and mouse ES cells (14–16). This is not entirely
surprising, taking into account the recently revealed associ-
ation of the translation machinery with lncRNAs (17).
In this article, we will cover recent advances regarding
the NMD mechanism, building on the roles of core NMD
factors, the functions of RNA helicases in NMD complex
assembly, as well as recent strategies used to identify novel
NMD factors. Finally, we will review the crucial role of the
NMD mechanism in buffering gene expression and its im-
pact on cell physiology.
PTC definition
Acrucial aspect of theNMDpathway is the ability to distin-
guish normal termination codons from PTCs. Despite the
relatively high conservation of NMD core factors across
evolution, the mechanism of PTC definition varies across
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Figure 1. Dual role of the Nonsense-mediated decay (NMD) pathway. NMD degrades PTC-containing transcripts (‘faulty’ transcripts) (top panel) and
also regulates the expression of naturally occurring transcripts (‘normal transcripts’), acting as a fine-tuning mechanism of gene expression (bottom panel).
Green spheres represent both ribosomal subunits, whereas red circles depict the core NMD factor, UPF1.
different species. In mammals, NMD is intimately linked to
pre-mRNA splicing, andmRNAs harboring a PTC 50 to 55
nucleotides upstream of the final exon–exon junction are ef-
ficiently degraded (18–21). This is signaled by the presence
of the exon junction complex (EJC), a multi-subunit pro-
tein complex, which is deposited 20 to 24 nucleotides up-
stream of an exon–exon junction during pre-mRNA splic-
ing (22,23). The EJC remains associated to the mRNA un-
til it is displaced by the translation machinery with the help
of the ribosome-associated protein PYM acting as an EJC
disassembly factor (24,25,26). Recent transcriptome-wide
analysis of EJC deposition established that EJCs are not
equally assembled at every exon junction, as previously hy-
pothesized (27,28); indeed, approximately half of all EJCs
are present at non-canonical positions (29). A remaining
challenge is to understand whether the observed variation
on EJC loading affects NMD efficiency. By contrast, PTC
definition occurs independently of exon boundaries in S.
cerevisiae, where the distance between the PTC and the
3′ end defines NMD, as proposed by the faux 3′ UTR
model (30,31). In Schizosaccharomyces pombe splicing en-
hances NMD; however, EJC components are not required
for NMD and what seems to enhance NMD is the proxim-
ity of the intron to the PTC (32). The presence of introns
is also not required to define PTCs in Drosophila or in C.
elegans, exposing a significant level of mechanistic diversity
in this critical step of the NMD process (33,34).
NMDmechanism and the role of RNAhelicases inNMDpro-
gression
The initial identification of factors with roles in the NMD
pathway was achieved bymeans of unbiased genetic screens
in Caenorhabditis elegans and Saccharomyces cerevisiae.
This led to the identification of seven genes in nema-
todes, termed smg-1–7 (suppressor with morphological ef-
fect on genitalia), given that mutations of these genes
led to abnormal morphogenesis of the male bursa and
the hermaphrodite vulva (35,36). Importantly, smg mutant
worms are viable, indicating that NMD is not essential in
nematodes. Similarly, three genes, termed UPF1–3 (for up-
frameshift), that are orthologues of C. elegans smg-2, smg-
3 and smg-4 genes, were identified in S. cerevisiae (37,38).
Homology searches led to the identification of orthologous
genes in other species, including Arabidopsis, Drosophila
and mammals (39).
RNA helicases have a central role in the mechanism
of NMD progression. In general, these enzymes can use
adenosine triphosphate (ATP) to translocate along nucleic
acids, potentially unwinding secondary structure and act-
ing to remodel RNA-protein complexes. Alternatively, they
might act as “placemarkers” remaining temporarily fixed in
a defined position while signaling to, or directly recruiting,
the degradation machinery (40,41). In the latter case, RNA
helicases clamp the RNA in an ATP-dependent fashion to
provide nucleation centers to assemble larger RNA-protein
complexes. The central component of the NMDpathway in
all organisms studied is the protein UPF1/SMG2, an ATP-
dependent RNA helicase of the SF1 superfamily, which
undergoes cycles of phosphorylation and dephosphoryla-
tion that are essential for NMD progression. Phosphory-
lation of UPF1 is carried out by the SMG1c complex,
comprised of the protein kinase SMG1, a phosphoinosi-
tide 3-kinase (PI3K)-like kinase and two additional sub-
units, SMG8 and SMG9 (42–44). Initially, UPF1 associates
with SMG1 and acts as a clamp, interacting directly with
the eukaryotic release factors eRF1 and eRF3 to form the
so-called surveillance complex (SURF) in the vicinity of
the PTC (Figure 2). Two subunits of the SMG1c complex,
SMG8 and theNTPase SMG9 associate tightly with SMG1
and regulate its activity through the induction of confor-
mational changes, with SMG8 binding to the preformed
SMG9-SMG1 complex and maintaining the kinase in its
inactive state (45–47). Subsequently, the SURF complex in-
teracts with UPF2, UPF3b and an EJC downstream of the
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Figure 2. Mechanism of NMD activation in mammalian cells, indicating
the transition from the surveillance complex (SURF) to the decay-inducing
complex (DECID). UPF1 and its associated kinase, SMG1, bind to the
eukaryotic release factors eRF1 and eRF3 to form the SURF complex in
the vicinity of a premature termination codon (PTC). A subsequent in-
teraction of this complex with UPF2, UPF3b and an exon junction com-
plex (EJC) downstream of the PTC triggers the formation of the DECID
complex, resulting in UPF1 phosphorylation and release of eRF1 and
eRF3. Phosphorylated UPF1 acts to recruit SMG5, SMG6 and SMG7,
and general mRNA degradation factors that lead to mRNA degradation.
PTC to form the decay-inducing complex (DECID) that
triggers UPF1 phosphorylation and dissociation of eRF1
and eRF3 (48–50) (Figure 2). As a consequence of the
remodeling of NMD complexes, UPF1 adopts its active
helicase confirmation due to the reorganization of its in-
hibitory domains through association with UPF2 (51–54).
The active UPF1 helicase functions as RNPase translocat-
ing along the mRNA, resolving secondary structure and
clearing the mRNA from proteins allowing access to nu-
cleases (55,56). The activated NMD complex consisting of
UPF1, UPF2 and UPF3b is translocated from its position
upstream of the EJC toward the 3′ of the EJC (57) (Fig-
ure 2). Subsequently, phosphorylated UPF1 associates with
the phospho-binding proteins SMG5, SMG6 and SMG7,
and general mRNA degradation factors and further re-
arrangements of this complex lead to mRNA degrada-
tion (58). SMG6 itself is an endonuclease, which can form
both phospho-dependent and phospho-independent inter-
actions with UPF1(59–62). SMG6 cleaves NMD targets in
the vicinity of the PTC (59,63), leading to the initiation
of NMD-mediated RNA degradation (64–66). SMG5 and
SMG7bind as a heterodimer to phosphorylatedUPF1. The
SMG7 subunit recruits directly POP2, the catalytic subunit
of the Deadenylase complex (67) and additionally initiates
decapping andXRN1-catalyzed 5′-3′ degradation (68). This
canonicalmammalianNMDpathway is not universal, since
alternative NMD branches that are independent of UPF2,
UPF3b or the EJC have been described (69–71).
Another RNA helicase with a role in EJC-mediated
NMD progression is eIF4AIII, a core component of
the EJC, that binds RNA in an ATP-dependent fash-
ion and recruits additional EJC factors, namely the het-
erodimer Y14/MAGOH and Barentz (BTZ, MLN51 or
CACSC3)(72,73) (Figure 3A). The crystal structure anal-
ysis of this complex revealed that eIF4AIII binds RNA in
an ATP-dependent fashion and recruits the other EJC core
factors (72,73). The heterodimer Y14/MAGOH stabilizes
the high affinity of eIF4AIII for RNA by preventing the
ATP hydrolysis of eIF4AIII and further primes it to bind
to Barentz (74,75). This arrangement allows eIF4AIII to
clamp several proteins onto RNA in a stable and sequence-
independent manner (76), which in turn is used by the
NMD machinery to recognize an aberrant PTC (Figure
3A). Thereby, a short motif of the core NMD factor UPF3b
binds to the EJC core factors and serves as a platform to as-
semble an active NMD complex (52,77). Two other DEAD
box proteinsDDX5 andDDX17 have also recently been de-
scribed to interact with UPF3b and this interaction seems
crucial for the degradation of a limited subset of NMD sub-
strates (78).
Additional RNA helicases also function as auxiliary fac-
tors in the NMD pathway. Through a process involving
their ATPase activities, the RNA helicases RUVBL1 and
RUVBL2 associate with the SURF complex and promote
the transition to the DECID complex (Figure 3B, upper
panel) (79). Given their tight association to the SMG1 ki-
nase, it can be speculated that RUVBL1, 2 contribute to
the regulation of the SMG1–8–9 complex by promoting the
activation of the large SMG1 kinase molecule. It was re-
cently shown that the RNA helicase DHX34, a member of
the DExH/D box family of proteins, associates with the
SURF complex and promotes the transition to the DE-
CID complex (80). Whereas members of this family have
been originally described as RNA helicases that unwind
RNA, it has also been found that other family members
function as RNPases that remodel RNA-protein interac-
tions (81,82). Thereby, DHX34 probably affects the remod-
eling of the SURF complex by promoting the dissociation
of the eukaryotic release factors eRF1 and eRF3 in anATP-
dependentmanner from the SURF complex at the PTC (80)
(Figure 3B, lower panel). It was recently shown that another
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Figure 3. Role of RNA helicases in NMD. (A) The exon junction complex (EJC) component, eIF4AIII, nucleates NMD factors, promoting interactions
with UPF2 and UPF3b. (B) RuvBL proteins promote activation of the SMG1 kinase during initial stages of NMD (upper panel). DHX34 promotes the
transition from the SURF to DECID complex (lower panel). (C) Function of the RNA helicases UPF1 and MOV10 in mRNP clearance.
UPF1-like RNA helicase, MOV10, preferentially binds to
3′ UTR regions, as is the case with UPF1 (83,84), and
contributes to degradation of UPF1-regulated transcripts
(85,86) (Figure 3C). Whether MOV10 helicase acts in a re-
dundant way with the UPF1 helicase as an RNA clearance
factor to resolve secondary structures and displace proteins
or if the two proteins perform distinct actions remains to be
clarified.
Non-EJC dependent models of NMD
Although it has been clearly established that the presence
of an EJC downstream of a PTC promotes NMD in mam-
malian cells, there is also increasing evidence of an ac-
tive NMD response in its absence. Therefore, NMD activa-
tion can rely on both EJC-dependent and EJC-independent
pathways (87). Alternative models for NMD activation that
do not require the presence of an EJC have been described
in other organisms, such as yeast and nematodes, but could
also operate in human cells (88). In particular, mRNAs har-
boring long 3′ UTRs have been shown to be sensitive to
NMD, irrespective of the presence of an EJC (83). A cen-
tral issue in NMD concerns the mechanism by which UPF1
is recruited to an NMD target. Recent studies showed that
UPF1 binds target RNAs before mRNA translation and
subsequently translating ribosomes displace it from coding
sequences leading to the accumulation of UPF1 at 3′ UTRs
(86,89). This observation challenges the assumption that
UPF1 recruitment marks mRNA for degradation. More-
over, UPF1 binding is not enriched on endogenous tran-
scripts that are upregulated in the absence of UPF1 (89,90).
A recent study proposed that binding of phosphorylated
UPF1 (P-UPF1) marks mRNAs for degradation. It was
shown that P-UPF1 is enriched on endogenous transcripts
degraded by NMD and predominantly unphosphorylated
UPF1 is released from non-targeted transcripts in an ATP-
dependent manner (91). However, P-UPF1 binding is not
exclusive to NMD targets, and it is also not apparent what
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makes UPF1 ‘stick’ preferentially to NMD targets and get
phosphorylated. Further clues about how UPF1 discrimi-
nates NMD targets come from a recently published RIP-
seq data of wild-type orATPase-deficientUPF1 cells, which
showed that UPF1 release from non-target mRNAs rather
thanUPF1binding itself wasmore important forNMDtar-
get selection. Faster dissociation of UPF1 from non-target
mRNAs requires correct ATPase activity of UPF1 and its
dissociation is enhanced by translation andPABC1binding,
also in an ATPase-dependent manner (92). Prematurely ter-
minated translation associated with a PTC leads to mRNA
degradation and it has been proposed that this is due to a
competition between UPF1 and the poly (A) binding pro-
tein, PABPC1, for binding to the translation release factor,
eRF3 (93). As such, the distance from the PTC to the poly
(A) tail is a determining factor on whether UPF1 will bind
near the PTC (30,71,94,95).
How are NMD targets recognized?
Even though our understanding of the NMD process is
rapidly increasing, the important question of how NMD
targets are selected in a global scale still remains unresolved.
So what rules governNMD target selection? Although both
EJC-dependent or independent models for target recog-
nition can be applicable to a selected number of targets,
the situation is less clear when analyzing high-throughput
NMD targets. For instance, profiling of transcripts regu-
lated by UPF1 revealed that many transcripts that are up-
regulated in the absence of UPF1 lack recognizable NMD
features, whereas many transcripts that would be predicted
to be NMD targets are unaffected by UPF1 depletion (96–
98).
The emerging picture suggests that likely no single NMD
feature will be globally sufficient to elicit NMD. Instead,
a combination of NMD-targeting and NMD-antagonizing
features contributes to determine NMD susceptibility of
any given mRNA. For some mRNAs, a canonical model
will apply, where a PTC situated 50–55 nucleotides up-
stream of an EJC elicits robust mRNA downregulation
(99). This is certainly the case for ‘faulty’ PTC-containing
transcripts for which NMD was originally described (see
Figure 1). In cells, these transcripts are usually rare, and
only produced as a result of genomic mutation or incorrect
RNA processing, and are often associated with diseases.
They are very efficiently degraded byNMD, thus preventing
the production of truncated proteins. For other mRNAs,
a distinct combination of NMD features will determine if,
and how efficiently, transcripts are degraded. This mode of
target determination is likely used for a vast majority of en-
dogenousNMD targets, whereNMD is an essential tool for
the fine-tuning of gene expression.
Additional NMD trans-acting factors and their role in the
regulation of NMD
A variety of strategies have been used in an attempt to un-
cover novel factors with a role in theNMDresponse, includ-
ing forward and reverse genetic screens and interactome
studies (Figure 4). A limitation of forward genetic screens
lays in their inability to identify genes that are essential for
viability. Additionally, the search of novel NMD factors us-
ing mutagenesis inC. eleganswas somewhat undermined by
the fact that almost 90% of smg mutations identified were
alleles of smg-1, smg-2 or smg-5 (35,36,100). This limitation
was overcome in reverse genetic screens using RNAi that
allows the identification of NMD factors independently of
their abundance or whether they are essential for cell sur-
vival.
In this context, the Interactome-Mass spectrometry ap-
proach emerges as a promising avenue for the identifica-
tion of abundant proteins that form part of NMD com-
plexes. A study using a yeast two-hybrid approach with
UPF1 as bait identified human proline-rich nuclear recep-
tor coregulatory protein 2 (PNRC2), as an interactor. This
factor was also found to interact with the decapping ac-
tivator, DCP1a, which led to a model whereby phospho-
rylated UPF1 acts as a platform to recruit PNRC2, pro-
viding a link with mRNA degradation (101,102). A com-
prehensive search using stable isotope labeling by amino
acids in cell culture (SILAC) was designed to distinguish
between proteins binding to either the hypo- or hyper-
phosphorylated form of UPF1. This resulted in the identifi-
cation of several RNA-binding proteins that preferentially
associate with hyper-phosphorylated UPF1 in the nucleus.
It also confirmed the eukaryotic translation initiation fac-
tor 3 (eIF3) as a UPF1 interactor (103). An interactome
search for the RNA helicase MOV10, which belongs to the
UPF1-like group of the helicase superfamily 1 (SF1)(104),
identified UPF1as the major interactor (86). Finally, use
of SMG1 as bait identified RuVB-like 1 (RUVBL1) and
RuVB-like 2 (RUVBL2) proteins, two adenosine triphos-
phatases that are part of (AAA+) family of proteins (Fig-
ures 3 and 4). These proteins have been reported to be in-
volved in several cellular functions, such as transcription,
DNA repair, telomeremaintenance andRNAmodification,
and also shown to act in the initial stages of the NMDpath-
way. Other SMG1 interactors identified in the same experi-
ment were RPB5, a subunit of RNA polymerases I, II and
III (105), as well as the homolog of a nematode NMD fac-
tor, termed SMG10, both of which also form part of the
RUVBL1/2 complex (79).
Use of a GFP-reporter-based RNAi screen in C. elegans
resulted in the identification of two novel NMD factors,
termed smgl-1 and smgl-2, that unlike smg genes are essen-
tial for viability, strongly suggesting that these two genes
have roles in NMD but also fulfill other essential functions
in nematodes (33) (Figure 4). Both genes are conserved
throughout evolution with clear orthologues in mouse, hu-
man and fugu. The C. elegans gene smgl-1 corresponds to
human NBAS (Neuroblastoma amplified sequence), also
known asNAG (forNeuroblastoma amplified gene). TheC.
elegans smgl-2 gene corresponds to humanDHX34 (DEAH
box protein 34), a DExH/D box protein (Figure 3B, lower
panel). Both NBAS and DHX34 are bona fide NMD fac-
tors both in human cells, as well as in zebrafish (33,106).
Identification of target genes regulated by DHX34 and
NBAS, in human, zebrafish and also in C. elegans revealed
a large co-regulation of targets between DHX34, NBAS
and the core NMD factor UPF1 in all species (11). The
NBAS gene was initially identified as a gene amplified in hu-
man neuroblastomas (107,108), and later found to encode
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Figure 4. NMD factors in yeast, nematodes and humans, indicating the method by which they were first identified.
a peripheral membrane protein that is a component of the
Syntaxin 18 complex, with a role in Golgi-to-endoplasmic
reticulum retrograde transport (109). Interestingly, muta-
tions in NBAS have been found in several human condi-
tions, including a hereditary short stature syndrome in the
Siberian Yakut population, characterized by optic nerve at-
rophy and Pelger–Hue¨t anomaly of granulocytes (SOPH
syndrome)(110), as well as in patients with a multisystem
disease involving liver, eye, immune system, connective tis-
sue and bone (111). Another recent report identified com-
pound heterozygous NBAS mutations with recurrent acute
liver failure in infancy in a group of patients of European
descent (112). It remains to be seen whether the pheno-
types of NBAS mutants are due to compromised NMD re-
sponse and/or defects in retrograde transport between the
ER and Golgi. Currently it is unclear, how NBAS con-
tributes to NMD in mechanistic terms; however, we have
recently found thatNBAS interacts with the coreNMD fac-
torUPF1 (Longman andCaceres, unpublished data). Com-
bined with a reported role in ER-Golgi vesicular trafficking
(109), we speculate thatNBASmight represent a connecting
link between NMD and transcripts entering the secretory
pathway. Interestingly, profiling of transcripts regulated by
NBAS showed significant enrichment for genes involved in
the cellular stress response (11).
The original NMD RNAi screen in C. elegans was revis-
ited; using a novel RNAi library that included many pre-
viously untested genes (113,114). This new screen resulted
in the identification of five novel nematode NMD genes
that are highly conserved throughout evolution and are re-
quired for NMD in nematodes (Figure 4) (115). Two of
their human homologs, GNL2 (ngp-1) and SEC13 (npp-
20), were also found to act in the NMD pathway in hu-
man cells (115). Moreover, expression profiling showed that
a significant proportion of transcripts that are regulated
by GNL2 and SEC13 were also largely upregulated when
canonical NMD factors UPF1 and UPF2 were depleted
(Casadio, Longman and Caceres, unpublished). The GNL2
gene encodes a putative GTPase, whose yeast homolog,
Nog2p, is involved in the processing of the pre-60S riboso-
mal particles (116), whereas human SEC13 is a constituent
of the endoplasmic reticulum and the nuclear pore complex
(NPC) (117). Whether these previously described roles of
GNL2 and SEC13 are related to their role in NMD will
require additional investigation. This screen also identified
the C. elegans gene, noah-2, which is present in Drosophila
melanogaster (nompA) but absent in humans, and has a role
as an NMD factor in fruitflies (115). Interestingly, the ex-
pression of nompA is restricted to the type I sensory organs
of the peripheral nervous system (PNS), suggesting the pos-
sibility that NMD can act in a tissue-specific manner.
Physiological role of the NMD response
The NMD response has been shown to be variable among
different cell-types and tissues (118,119), and even among
individuals where this can be correlatedwith clinical presen-
tations of human diseases caused by the presence of a PTC
(13).What are the mechanisms that lead to a variable NMD
response? One such mechanism could be the variation in
the relative abundance of RNPS1, a peripheral component
of the EJC, observed in different HeLa cells subtypes that
correlates well with the magnitude of the NMD response
(120). The relatively recent realization that NMD acts to
regulate endogenous gene expression of mRNAs lacking a
PTC strongly suggested that the NMD response itself has
to be precisely regulated in order to avoid undesirable al-
terations to the gene expression program of cells and tis-
sues. One way to regulate the NMDactivity is via a negative
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feedback regulatory network whereby a large proportion of
core NMD factors are negatively regulated by NMD. This
feedback loop was initially observed in mammalian cells,
and was later also found in nematodes, zebrafish and plants
(118).
The NMD pathway is not essential in nematodes where
mutations in the core NMD factors (smg1–7) lead to dis-
crete phenotypes (35). A similar scenario is found in yeast,
where the loss of the Upf proteins has no obvious effect
on growth (37). By contrast, targeted disruption of mam-
malian core NMD factors results in embryonic lethality in
the mouse, as observed for Upf1 (121), Upf2 (98) or Smg6
(122). Along the same lines, Smg1 is required for embryoge-
nesis and was shown to regulate target genes via alternative
splicing coupled to NMD (123). The phenotypes observed
with inactivation of mouse core NMD genes could be inter-
preted as indicating an essential role for the NMD pathway
in mammals. An alternative explanation is related to the
existence of additional cellular functions for UPF proteins
(124). These include a reported role for UPF1 in genome
stability in human cells (125), as well as its role in the SMD
pathway (Staufen-mediated decay), whereby UPF1 is re-
cruited to the 3′ UTRs of mRNAs bound by the RNA-
binding protein STAUFEN 1 and induces mRNA degra-
dation (126,127). UPF1 has also been shown to be involved
in regulating the degradation of histone mRNAs, where it is
recruited by the stem-loop binding protein (128). The Smg1
gene has also an additional role in genotoxic stress (129).
As in the mouse system, Drosophila Upf1 and Upf2 are
also required for animal development and viability (130).
By contrast, Drosophila Upf3 plays a peripheral role in the
degradation of most NMD targets and is not required for
development or viability (131). The role of the NMD re-
sponse and/or of individual NMD factors during develop-
ment and also during neuronal development has recently
been reviewed (93,119). Below, we will focus on a few exam-
ples on how the NMD pathway impacts on several physio-
logical processes, including the stress response, the immune
response and on viral replication.
Stress response
In response to stress, cells initiate a complex cascade of
events leading to dynamic changes in gene expression that
are designed to alleviate stress and restore homeostasis, or
trigger apoptosis. It was observed that NMD is repressed
by a variety of stress conditions, such as hypoxia, nutri-
ent deprivation or infection (132,133). This inhibition is, at
least partially, mediated by phosphorylation of the trans-
lation initiation factor eIF2, which leads to inhibition of
mRNA translation and is a common step for the initiation
of many stress pathways (134). This results in many tran-
scripts that are normally degraded by NMD being upreg-
ulated, including those encoding factors that are required
during stress response, helping to establish a more robust
stress response and increasing cell survival (135). NMDalso
modulates the unfolded protein response (UPR), which is
triggered by endoplasmic reticulum (ER) stress. A chronic
activation of the UPR contributes to the pathogenesis of a
wide variety of human disorders; thus,UPRactivationmust
be tightly regulated. It was shown that NMD directly tar-
gets mRNAs encoding several essential UPR components,
including many UPR sensors (136–138). In this way, NMD
controls the threshold of UPR activation, and prevents the
inappropriate response to harmless levels of stress (136).
Additionally, NMD inhibition itself, can also induce UPR
(137,138). It is possible that inhibition of NMD overloads
the ER with truncated misfolded proteins that themselves
could generate sufficient stress signal. However, the extent
of this NMD-mediated effect onUPR activation remains to
be determined. Moreover, NMD inhibition leads to the ac-
tivation of autophagy that decreases accumulation of detri-
mental proteins in the cell. Autophagy activation is partially
due to the stabilization of the NMD target ATF4 mRNA
(139). Conversely, hyperactivation of the NMD response
blocks the induction of autophagy in response to cellular
stresses. In summary, under normal conditions, NMD ac-
tivity is required for protecting cells from inappropriate ac-
tivation of UPR by innocuous stimuli. In response to stress,
NMD inhibition augments UPR response by increased ex-
pression of transcripts that encode UPR sensors such as
IRE1. NMD re-activation then helps terminate the stress
response and restore homeostasis. Therefore, NMD helps
to fine-tune the threshold of UPR response, and the activ-
ity of NMD is in turn regulated by the UPR.
Immune response
A robust immune response is needed for preventing or lim-
iting infection; however, if left uncontrolled it can lead to
pathologies or death. It is therefore crucial that organisms
are able to maintain immune homeostasis by suppressing or
switching off the immune response. It was recently proposed
that NMD plays an active role in the regulation of the im-
mune response. Cytokines are signalingmolecules (e.g. IL-6
or TNF) thatmodulate the inflammatory immune response.
In response to infection, cytokines are rapidly upregulated
and initiate an immune response cascade via binding to
their receptors at the surface of the cells. It was recently
shown that UPF1, together with the RNA-binding protein,
Regnase-1, regulates the early (acute) phase of inflamma-
tion response by degrading cytokine mRNAs. Regnase-1
binds to a stem-loop in 3′ UTRs of translationally active cy-
tokine mRNAs and acts together with UPF1 to downregu-
late these targets, whereas the role of another RNA-binding
protein Roquin, that controls the late (chronic) phase of in-
flammation, is independent of UPF1 (140). Although it is
not entirely clear that the action of Regnase-1 together with
UPF1 represents NMDper se, the helicase activity ofUPF1
is required. Another way that NMD could affect the inflam-
mation response is via controlling the stability of the cy-
tokine receptor mRNAs. One recently documented exam-
ple is the complex regulation of the human CCR5 cytokine
receptor mRNA stability (141). CCR5 mRNA harbors a
programmed −1 ribosomal frameshift (−1PRF) signal di-
rected by an mRNA pseudoknot that is formed by mRNA–
miRNA interactions. This−1PRF directs the translating ri-
bosome to a PTC, leading to mRNA downregulation.
A better understanding of NMD modulation during im-
mune response can be useful for the development of new
therapies for autoimmune diseases or cancer. For exam-
ple, upregulation ofNMDduring chronic inflammation can
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help to restore immune homeostasis. On the other hand,
blocking NMD in cancer may result in the synthesis of
tumor-specific proteins that can increase natural immune
response directed against the tumor (142). This could in-
deed be a feasible approach, as it was recently demonstrated
that the increase of intracellular calcium by commonly used
cardiac glycosides inhibits NMD (143). A role for NMD in
the control of the immune response is also seen in plants,
where this pathway contributes to innate immunity in Ara-
bidopsis (144–146). NMD acts to downregulate numerous
TIR domain-containing, nucleotide-binding, leucine-rich
repeat (TNL) immune receptor-encoding mRNAs. Bacte-
rial infection of plants leads to host-programmed inhibition
of NMD, resulting in the upregulation of those naturally
NMD-regulated TNL transcripts. By contrast, constitutive
NMDactivity prevents accumulation of TNL receptors and
impairs plant defense. Thus, a mechanism of host-regulated
NMD contributes to disease resistance by controlling the
threshold for activation of TNL resistance pathways (145).
Viral replication
Apart from its role in immune response regulation, NMD
also serves as a natural barrier to virus replication. A
genome-wide RNAi screen in HeLa cells looking for host
factors that restrict virus replication identified several com-
ponents of the NMD pathway (147). Downregulation of
UPF1, SMG5 and SMG7 led to an increase in the level of
viral proteins and higher viral infection. Viruses have also
evolvedmechanisms to evadeNMD-mediated degradation.
For example, Rous sarcoma virus harbors a stability ele-
ment in its 3′ UTR (RSE, for Rous sarcoma virus stabil-
ity element) that protects the viral RNA fromNMD. It was
hypothesized that this viral stability element may prevent
UPF1 function (148,149). The HTLV-1 virus Tax and Rex
proteins also inhibit NMD (150,151); however, their mode
of action is not entirely clear. It has been shown that the Tax
protein interacts withUPF1 and with a component of eIF3,
INT6 that also has a proposed role in NMD. Tax increases
the accumulation of phosphorylatedUPF1 in P- bodies and
this leads to enhanced stability of HTLV-1 mRNAs (150).
Similarly, plants also employ NMD to restrict viral repli-
cation by destabilizing viral transcripts containing internal
stop codons or long 3′ UTRs. As expected, plant viruses
also evolvedmechanisms that either evadeNMD, ormodify
host endogenous NMD activity (152). Therefore, the host
NMD response that reduces viral infection and is in turn
counteracted by viruses modulating NMD seems to be an
evolutionarily conserved relationship.
NMD inhibitors and therapeutic possibilities
NMD activity can be modulated by many cellular pertur-
bations. Treatment of human cells with chemotherapeutic
compounds results in a pronounced decline in NMD ac-
tivity. This is partly due to the proteolytic production of a
dominant-negative form of the key NMD factor UPF1 and
results in the upregulation of genes involved in the response
to apoptotic stresses, leading to cell death (153). Further-
more, caspases cleave both UPF1 and UPF2 during apop-
tosis, impairing the NMD response (154). In an interesting
link with a human disease, it has been recently reported that
increased expression of the double homeobox transcription
factor DUX4, which is observed in patients with the mus-
cular dystrophy, Facioscapulohumeral muscular dystrophy
(FSHD), triggers proteolytic degradation of UPF1, leading
to pronounced NMD inhibition. DUX4 mRNA is itself an
NMD target, thus, inhibition of NMD by DUX4 protein
stabilizes DUX4 mRNA through a double-negative feed-
back loop in FSHD muscle cells (155).
The development of inhibitors of NMD could be impor-
tant to gain mechanistic insights into NMD function but
could also prove to be important for therapeutic purposes.
The search for NMD inhibitors is currently approached by
means of several strategies. A screen in HeLa cells stably ex-
pressing an NMD reporter that used a library of clinically
licensed compounds identified 5-azacytidine, an analog of
the naturally occurring nucleoside cytidine, which has been
previously approved for the treatment of myelodysplastic
syndrome and myeloid leukemia (156). This inhibitory ef-
fect of 5-azacytidine on NMD, depends on the induction
of MYC expression, which was previously shown to in-
hibit NMD activity (157). A small molecule inhibitor of
NMD, termed NNMDI 1, was shown to stabilize hyper-
phosphorylated isoforms of UPF1 and to compromise its
interaction with SMG5 (158). Compounds that disrupt the
SMG7-UPF1 complex and inhibit NMD have also been re-
cently identified. These compounds when combined with a
PTC ‘read-through’ drug led to restoration of full-length
p53 protein in cells harboring a PTC-mutated p53 (159).
Pateamine A (PatA), a natural product first isolated from
marine sponges, was also shown to inhibit NMD through a
direct interaction with the EJC component, eIF4AIII. Im-
portantly, this PatA-mediated inhibition of NMD is inde-
pendent of the previously reported role of this compound
in inhibition of translation initiation (160). The dietary
compound curcumin has also been shown to inhibit the
NMD pathway by downregulating the expression of core
NMD factors at the transcriptional level (161). Finally,
pyrimidine derivatives have been identified as hSMG-1 ki-
nase inhibitors (162). In many cases, expression of a PTC-
containing mRNA can be advantageous for the cell, when
the production of a truncated protein is less harmful than
elimination of its encoding mRNA by NMD. This is par-
ticularly important in the case of certain human diseases
caused by mutations that introduce PTCs. A number of
drugs have been identified that induce suppression of trans-
lation termination at PTCs in mammalian cells (163,164).
This PTC suppression therapy, which is currently in clin-
ical trials for treatment of several genetic diseases caused
by PTCs, can be combined with strategies to inhibit NMD.
One such strategy of NMD inhibition combined with PTC
read-through was recently reported (165). Here, antisense
oligonucleotides (ASOs) designed to block assembly of an
EJC downstream of PTCs and inhibit NMD in a gene-
specific fashion were combined with read-through com-
pounds. This approach restored expression of full length
protein from a nonsense-mutant allele (165). Thus, these
complementary strategies could have an important role in
alleviating the phenotypic consequences of a wide range of
genetic diseases caused by the presence of a PTC.
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CONCLUSION
In the last few years, there has been a significant increase in
our understanding on how the NMD mechanism operates,
how the different sub-complexes are assembled and the role
of some of the NMD trans-acting factors. The realization
of a more general role for NMD in regulating gene expres-
sion raised some new questions, such as how is theNMD re-
sponse buffered, how are non-PTC-containing endogenous
transcripts targeted by the NMD machinery and whether
there are more trans-acting factors yet to be identified. A
full understanding of the role of the NMD response in the
physiology of cells represents both an interesting mechanis-
tic challenge but also an opportunity for future therapeutic
interventions.
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